A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation
Laboratory studyOther animalsWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Rats given an intraplantar injection of carrageenan into the paw to induce acute inflammation
- Dose used in the study
- Oral co-micronised PEA and polydatin composite, compared with micronised PEA plus polydatin given as separate compounds
- Duration
- Single-dose acute carrageenan model, effects tracked over time after injection
- What was measured
- Paw swelling, cytokine release in paw fluid, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 levels, spinal MnSOD, IkB-alpha and NF-kB, thermal hyperalgesia and mechanical allodynia
What the authors reported
This laboratory study found:
- The co-micronised PEA and polydatin composite reduced paw swelling, cytokine release, nitrotyrosine formation and enzyme expression, and lowered thermal hyperalgesia and mechanical allodynia.
- At the spinal cord, the composite raised MnSOD expression and blocked IkB-alpha breakdown and NF-kB movement into the nucleus.
- Its anti-inflammatory and anti-hyperalgesic effects were larger than those of PEA and polydatin given together as separate compounds.
Limits of this study
A rat model of carrageenan-induced paw inflammation; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 27095683 · doi:10.1016/j.ejphar.2016.03.033
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.